We apply scientific rigour to evaluate the economic and clinical value of healthcare interventions using both traditional and innovative perspectives and methods.
Evidence review and synthesis
We help our clients ensure that they have the full picture regarding the evidence landscape for their product. Our evidence synthesis specialists work with clients to develop a fit-for-purpose review strategy and evidence methodologies, considering their ultimate project goals. Following the gathering of evidence, we can advise on the best approach to statistical analysis, from simpler ITC and NMA approaches to more advanced methods in cases of sparse evidence networks or other data concerns. Via a process of feasibility assessment, we determine the most suitable approach to take to generate estimates of comparative efficacy and safety.
Health economic modelling
We partner with clients to develop health economic strategy, leveraging both clinical trial data and real-world evidence. We are experienced in developing academically robust models which are transparent and user-friendly, ensuring ease of use for a range of audiences, both internal and external.
Our experience spans early economic modelling, global cost-effectiveness and budget impact modelling to support HTA, as well as country adaptations. We are also experienced in the development of disease transmission model and natural history models using a variety of approaches (multi-state Markov to compartmental models). We leverage our team’s multidisciplinary nature, comprising health economists, epidemiologists, statisticians, clinicians and actuaries, to ensure the approach and supporting data are as robust as possible.
Innovative value-based reimbursement solutions
Value-based contracting has the potential to improve patient access to innovative therapies by better aligning incentives between payers and manufactures. However, uncertainty across stakeholders and the wide skillsets required to put such agreements in place often limit adoption and implementation. We have a track record of combining the skillsets of actuaries, data scientists, epidemiologists and clinicians to support clients through all stages of OBA design and implementation.
Capturing the wider value of therapeutics
Health is a key driver of economic prosperity yet we rarely capture the wider value that therapies and other interventions can deliver to health systems and wider society. We work with clients to estimate this across two areas:
- Wider societal value of interventions including averted productivity loss and informal care including additional stratification to assess impacts upon existing inequalities within therapeutic areas.
- More novel additional value elements that are becoming increasingly of interest and consideration in Health Technology Assessments such as transmission, enablement, diversity and insurance value.
Explore our solutions
We integrate a wealth of health and health-related datasets and develop bespoke interactive visualisations to make it accessible and rapid for clients to glean insights across a range of areas.
Multimorbidity, living with two or more conditions is one of the biggest challenges facing patients and health systems today. We leverage real world datasets and innovative approaches to generate evidence that identifies patient groups with the greatest unmet needs in a more holistic manner that reflects the drivers of ill health.
We understand that developing a comprehensive Real-World Evidence (RWE) strategy is not just a necessity, but a game-changer for life science companies. Leveraging our deep expertise, we help our clients develop holistic strategies that plan for all RWE needs across all stages of the medicine lifecycle.
Supporting our clients to achieve equitable health outcomes is a golden thread throughout our work. We combine our expertise to translate evidence into change and apply population health analytics to help reduce inequalities in health and health outcomes.